Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000045283 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An In Vitro and In Vivo Assessment of Antitumor Activity of Extracts Derived from Three Well-Known Plant Species.
Plants (Basel)
April 2023
Department of Pharmaceutical Botany, Iuliu Hatieganu University of Medicine and Pharmacy, 8 Victor Babes Street, 400347 Cluj-Napoca, Romania.
One of the objectives of this study consists of the assessment of the antitumor activity of several extracts from three selected plant species: L., L., and L.
View Article and Find Full Text PDFCyclophosphamide-associated bladder cancers and considerations for survivorship care: A systematic review.
Urol Oncol
October 2021
Harvard Medical School, 25 Shattuck Street, Boston, MA 02115; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215; Division of Urologic Surgery, Brigham and Women's Hospital, 45 Francis Street, Boston, MA, 02115. Electronic address:
Purpose: We performed a systematic review to assess the clinical features of cyclophosphamide-associated bladder cancer.
Materials And Methods: MEDLINE, Web of Science, and Cochrane Library were searched from inception to August 2020 according to PRISMA guidelines. Studies that associated bladder cancer with prior cyclophosphamide use on an individual level were included.
Plerixafor and autologous stem cell transplantation: impressive result in a chemoresistant testicular cancer patient treated with high-dose chemotherapy.
Anticancer Drugs
July 2013
Department of Hematology and Oncology, Hematology Unit with Bone Marrow Transplantation, Santa Maria Goretti Hospital, Italy.
Plerixafor, a CXCR4 antagonist, induces the rapid release of hematopoietic progenitor stem cells from the bone marrow into peripheral blood; it is approved for autologous hematopoietic progenitor stem cell mobilization in multiple myeloma and non-Hodgkin's lymphoma patients. We report the case of a 34-year-old patient with metastatic testicular embryonal carcinoma who was extensively and in vain pretreated with chemotherapy and failed to mobilize an adequate number of hematopoietic progenitor stem cells following high-dose chemotherapy, with the support of granulocyte colony-stimulating factors. After a cycle of high-dose cyclophosphamide associated with granulocyte colony-stimulating factors, plerixafor was administered to the patient, with the clinical evidence of an increase in hematopoietic progenitor stem cells in the peripheral blood.
View Article and Find Full Text PDFCyclophosphamide associated bladder cancer--a highly aggressive disease: analysis of 12 cases.
J Urol
December 1996
Department of Urologic Surgery, University of Minnesota Hospital and Clinic, Minneapolis, Minnesota, USA.
Purpose: We gained knowledge of the etiology, treatment and prevention of cyclophosphamide associated urothelial cancer.
Materials And Methods: The medical records of 6 men and 6 women (mean age 55 years) with cyclophosphamide associated bladder cancer were reviewed.
Results: All tumors were grade 3 or 4 transitional cell carcinoma.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!